Safety and Immunogenicity of Recombinant Human Thrombin: A Pooled Analysis of Results from 10 Clinical Trials-Reference-Cited by-同舟云学术

Safety and Immunogenicity of Recombinant Human Thrombin: A Pooled Analysis of Results from 10 Clinical Trials

Published:2012-10-26 Issue:11 Volume:32 Page:998-1005
ISSN:0277-0008
Container-title:Pharmacotherapy: The Journal of Human Pharmacology and Drug Therapy
language:en
Short-container-title:Pharmacotherapy

Author:

Singla Neil K.¹,Foster Kevin N.²,Alexander W. Allan³,Pribble John P.³

Affiliation:

1. Lotus Clinical Research; Pasadena; California

2. Arizona Burn Center at Maricopa Medical Center; Phoenix; Arizona

3. ZymoGenetics; a Bristol-Myers Squibb Company; Seattle; Washington

Publisher

Wiley

Subject

Pharmacology (medical)

Reference19 articles.

1. ZymoGenetics, a Bristol-Myers Squibb Company Prescribing information: RECOTHROM ® Seattle, WA 2009

2. King Pharmaceuticals, a Pfizer Company Prescribing information: Thrombin-JMI ® 2011

3. Ethicon, Inc., a J & J Company Prescribing information: EVITHROM ® 2010

5. Immunogenicity of recombinant human proteins: causes and consequences;Schellekens;J Neurol,2004

Cited by 10 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Autoimmune clotting dysfunction;The Rose and Mackay Textbook of Autoimmune Diseases;2024

4. Autoimmune Clotting Dysfunction;The Autoimmune Diseases;2020